|
EGFR mutation subtype, No. (%)
|
|
Exon 19 deletion
|
68 (80.0)
|
16.0
|
0.31 (0.14–0.71)a
|
0.006
|
0.27 (0.12–0.58)a
|
0.001
|
|
Exon 21 L858R point mutation
|
11 (12.9)
|
8.7
|
0.34 (0.13–0.94)b
|
0.037
|
0.39 (0.15–1.03)b
|
0.058
|
|
Rare and complex mutation
|
6 (7.1)
|
9.0
| | | | |
|
Baseline symptomatic brain metastases, No. (%)
|
|
No
|
60 (70.6)
|
14.3
|
0.67 (0.34–1.27)g
|
0.209
|
0.70 (0.37–1.32)g
|
0.267
|
|
Yes
|
25 (29.4)
|
13.5
| | | | |
|
ECOG performance status, No. (%)
|
|
0–1
|
69 (81.2)
|
13.8
|
0.86 (0.39–1.90)g
|
0.703
|
0.86 (0.39–1.90)g
|
0.703
|
|
2–4
|
16 (18.8)
|
15.9
| | | | |
|
Abnormal organ function, No. (%)
|
|
No
|
70 (82.4)
|
14.3
|
0.53 (0.25–1.09)g
|
0.086
|
0.50 (0.25–1.00)g
|
0.050
|
|
Yes
|
15 (17.6)
|
8.8
| | | | |
|
Afatinib dose adjustment, No. (%)
|
|
Dose reduced
|
26 (30.6)
|
15.9
|
0.93 (0.44–1.99)c
|
0.854
|
0.72 (0.39–1.34)c
|
0.301
|
|
Dose increased
|
10 (11.8)
|
13.5
|
2.35 (0.86–6.47)d
|
0.098
|
2.13 (0.93–4.88)d
|
0.075
|
|
Starting dose maintained
|
49 (57.6)
|
13.4
| | | | |
|
Optimal afatinib dose, No. (%)
|
|
Less than 40 mg once daily
|
51 (60.0)
|
15.9
|
0.64 (0.32–1.28)e
|
0.209
|
0.47 (0.21–1.08)e
|
0.075
|
|
50 mg once daily
|
4 (4.7)
|
13.5
|
0.97 (0.25–3.78)f
|
0.962
|
1.03 (0.27–4.01)f
|
0.962
|
|
40 mg once daily
|
30 (35.3)
|
13.4
| | | | |
